Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

Michael G. Agadjanyan, Anahit Ghochikyan, Irina Petrushina, Vitaly Vasilevko, Nina Movsesyan, Mikayel Mkrtichyan, Tommy Saing, David H. Cribbs

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Immunization of amyloid precursor protein transgenic mice with fibrillar β-amyloid (Aβ) prevents Alzheimer's disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Aβ, containing the B and T cell self epitopes of Aβ, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6% of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Aβ Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Aβ immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Aβ in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-btading peptide (PADRE). Importantly, the PADRE-Aβ1-15 sequence lacks the T cell epitope of Aβ. Immunization of BALB/c mice with the PADRE-Aβ1-15 epitope vaccine produced high titers of anti-Aβ Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Aβ peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.

Original languageEnglish (US)
Pages (from-to)1580-1586
Number of pages7
JournalJournal of Immunology
Volume174
Issue number3
StatePublished - Feb 1 2005

Fingerprint

Alzheimer Vaccines
B-Lymphocyte Epitopes
Immunodominant Epitopes
T-Lymphocyte Epitopes
HLA-DR Antigens
Amyloid
Alzheimer Disease
Vaccines
Meningoencephalitis
Peptides
Epitopes
Amyloid beta-Protein Precursor
Clinical Trials
T-Lymphocytes
Immunotherapy
Transgenic Mice
Immunization
Autoimmunity
B-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Agadjanyan, M. G., Ghochikyan, A., Petrushina, I., Vasilevko, V., Movsesyan, N., Mkrtichyan, M., ... Cribbs, D. H. (2005). Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. Journal of Immunology, 174(3), 1580-1586.

Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. / Agadjanyan, Michael G.; Ghochikyan, Anahit; Petrushina, Irina; Vasilevko, Vitaly; Movsesyan, Nina; Mkrtichyan, Mikayel; Saing, Tommy; Cribbs, David H.

In: Journal of Immunology, Vol. 174, No. 3, 01.02.2005, p. 1580-1586.

Research output: Contribution to journalArticle

Agadjanyan, MG, Ghochikyan, A, Petrushina, I, Vasilevko, V, Movsesyan, N, Mkrtichyan, M, Saing, T & Cribbs, DH 2005, 'Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide', Journal of Immunology, vol. 174, no. 3, pp. 1580-1586.
Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. Journal of Immunology. 2005 Feb 1;174(3):1580-1586.
Agadjanyan, Michael G. ; Ghochikyan, Anahit ; Petrushina, Irina ; Vasilevko, Vitaly ; Movsesyan, Nina ; Mkrtichyan, Mikayel ; Saing, Tommy ; Cribbs, David H. / Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. In: Journal of Immunology. 2005 ; Vol. 174, No. 3. pp. 1580-1586.
@article{cea59734dce54844ab88ed106328a442,
title = "Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide",
abstract = "Immunization of amyloid precursor protein transgenic mice with fibrillar β-amyloid (Aβ) prevents Alzheimer's disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Aβ, containing the B and T cell self epitopes of Aβ, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6{\%} of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Aβ Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Aβ immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Aβ in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-btading peptide (PADRE). Importantly, the PADRE-Aβ1-15 sequence lacks the T cell epitope of Aβ. Immunization of BALB/c mice with the PADRE-Aβ1-15 epitope vaccine produced high titers of anti-Aβ Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Aβ peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.",
author = "Agadjanyan, {Michael G.} and Anahit Ghochikyan and Irina Petrushina and Vitaly Vasilevko and Nina Movsesyan and Mikayel Mkrtichyan and Tommy Saing and Cribbs, {David H.}",
year = "2005",
month = "2",
day = "1",
language = "English (US)",
volume = "174",
pages = "1580--1586",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from β-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide

AU - Agadjanyan, Michael G.

AU - Ghochikyan, Anahit

AU - Petrushina, Irina

AU - Vasilevko, Vitaly

AU - Movsesyan, Nina

AU - Mkrtichyan, Mikayel

AU - Saing, Tommy

AU - Cribbs, David H.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Immunization of amyloid precursor protein transgenic mice with fibrillar β-amyloid (Aβ) prevents Alzheimer's disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Aβ, containing the B and T cell self epitopes of Aβ, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6% of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Aβ Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Aβ immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Aβ in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-btading peptide (PADRE). Importantly, the PADRE-Aβ1-15 sequence lacks the T cell epitope of Aβ. Immunization of BALB/c mice with the PADRE-Aβ1-15 epitope vaccine produced high titers of anti-Aβ Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Aβ peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.

AB - Immunization of amyloid precursor protein transgenic mice with fibrillar β-amyloid (Aβ) prevents Alzheimer's disease (AD)-like neuropathology. The first immunotherapy clinical trial used fibrillar Aβ, containing the B and T cell self epitopes of Aβ, as the immunogen formulated with QS21 as the adjuvant in the vaccine. Unfortunately, the clinical trial was halted during the phase II stage when 6% of the participants developed meningoencephalitis. The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Aβ Abs may have been therapeutic to the AD patients. Therefore, to reduce the risk of an adverse T cell-mediated immune response to Aβ immunotherapy we have designed a prototype epitope vaccine that contains the immunodominant B cell epitope of Aβ in tandem with the synthetic universal Th cell pan HLA DR epitope, pan HLA DR-btading peptide (PADRE). Importantly, the PADRE-Aβ1-15 sequence lacks the T cell epitope of Aβ. Immunization of BALB/c mice with the PADRE-Aβ1-15 epitope vaccine produced high titers of anti-Aβ Abs. Splenocytes from immunized mice showed robust T cell stimulation in response to peptides containing PADRE. However, splenocytes from immunized mice were not reactivated by the Aβ peptide. New preclinical trials in amyloid precursor protein transgenic mouse models may help to develop novel immunogen-adjuvant configurations with the potential to avoid the adverse events that occurred in the first clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=12444268257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444268257&partnerID=8YFLogxK

M3 - Article

C2 - 15661919

AN - SCOPUS:12444268257

VL - 174

SP - 1580

EP - 1586

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -